This company has been acquired
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Opiant Pharmaceuticals Salute del bilancio
Salute finanziaria criteri di controllo 5/6
Opiant Pharmaceuticals has a total shareholder equity of $20.5M and total debt of $13.8M, which brings its debt-to-equity ratio to 67.1%. Its total assets and total liabilities are $42.0M and $21.4M respectively.
Informazioni chiave
67.1%
Rapporto debito/patrimonio netto
US$13.76m
Debito
| Indice di copertura degli interessi | n/a |
| Contanti | US$35.38m |
| Patrimonio netto | US$20.50m |
| Totale passività | US$21.45m |
| Totale attività | US$41.95m |
Aggiornamenti recenti sulla salute finanziaria
Recent updates
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates
Aug 13
Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment
Aug 08Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate
Aug 05Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts
Mar 21Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 19These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well
Nov 17Opiant Pharmaceuticals: Assessing Recent Insider Buying
Sep 19Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts
Aug 07Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
Jun 09The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts
Mar 06News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts
Mar 05Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.
Jan 27Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003
Dec 14Opiant Pharmaceuticals receives $50M in convertible debt financing
Dec 10Analisi della posizione finanziaria
Passività a breve termine: OPNT's short term assets ($38.5M) exceed its short term liabilities ($7.0M).
Passività a lungo termine: OPNT's short term assets ($38.5M) exceed its long term liabilities ($14.4M).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: OPNT has more cash than its total debt.
Riduzione del debito: OPNT's debt to equity ratio has increased from 0% to 67.1% over the past 5 years.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: OPNT has sufficient cash runway for more than a year based on its current free cash flow.
Previsione Cash Runway: OPNT has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 27.7% each year.